Résultats de la recherche

search

Rechercher les filtres

Organisation
Genelux Corporation
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
28 mars 2025 16h10 HE | Genelux Corporation
– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
25 mars 2025 08h31 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an...
GENELUX-Final-Logo-Notagline.png
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease
25 mars 2025 08h30 HE | Genelux Corporation
- U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval - WESTLAKE VILLAGE, Calif., March ...
GENELUX-Final-Logo-Notagline.png
Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
25 mars 2025 08h30 HE | Genelux Corporation
–  Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a...
Matthew Pulisic, new Chief Financial Officer of Genelux
Genelux Corporation Announces New Chief Financial Officer
03 févr. 2025 06h45 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
13 déc. 2024 07h01 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
14 nov. 2024 16h05 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
06 nov. 2024 16h01 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
22 oct. 2024 16h01 HE | Genelux Corporation
– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
09 oct. 2024 16h15 HE | Genelux Corporation
WESTLAKE VILLAGE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...